Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|169|5|754-756

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.169, Iss.5, 2015-06, pp. : 754-756

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 1, 2015-04 ,pp. : 36-43

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma

By  

Acta Haematologica, Vol. 134, Iss. 4, 2015-0 ,pp. : 229-230

Karger

Access to resources Recommend Favorite

Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 605-606

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 647-652

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma

By  

Oncology, Vol. 85, Iss. 4, 2013-09 ,pp. : 223-227

Karger

Access to resources Recommend Favorite